CPT® Code 0490T

Autologous adipose-derived regenerative cell (ADRC) therapy is a specialized treatment approach utilized for managing scleroderma in the hands. Scleroderma is a rare and chronic connective tissue disorder that leads to the hardening of the skin, subcutaneous tissues, blood vessels, and potentially major organs. When scleroderma affects the hands, it can precede systemic involvement by several months or even years, resulting in significant dysfunction and disability. The manifestations of scleroderma in the hands can include ischemia, which is a reduction in blood flow; fibrosis, or the thickening and scarring of connective tissue; painful digital ulcers; sclerodactyly, characterized by tightness and thickening of the skin on the fingers; Raynaud’s phenomenon, which involves episodes of reduced blood flow to the fingers; pale skin discoloration due to narrowed blood vessels; calcium deposits in soft tissues; as well as swelling, puffiness, joint pain, and stiffness. The use of ADRCs, which are rich in stem cells, aims to repair damaged tissues and modify the progression of the disease through processes such as angiogenesis, which promotes the formation of new blood vessels. This therapy can lead to reduced inflammation and fibrosis, ultimately preserving hand function and enhancing the quality of life for individuals affected by this debilitating condition. The procedure involves harvesting adipose cells from the patient using a minimally invasive small volume liposuction technique. The harvested ADRCs are then prepared on the same day using a proprietary system that includes incubation with enzymes to facilitate cell dissociation, followed by the removal of non-viable cells and debris. After preparation, the concentration and dilution of the ADRCs are assessed, and the cells are injected into the patient’s hand(s) to provide therapeutic benefits.